Back to today’s briefing

Story perspectives

Hanmi's Efpeglenatide: Game-Changer for Obesity Treatment by 2027

1/16/2025

37 3

Summary

Story summary

Hanmi Pharmaceutical is gearing up to make waves in the obesity drug market with its innovative Efpeglenatide, a "Korean-customized" treatment currently in Phase 3 trials and expected to launch in 2027. This GLP-1 receptor agonist promises safe weight loss with minimal side effects, while Hanmi also explores two additional candidates, HM15275 and HM17321, to cater to various obesity challenges.

1 of 1

Story summary

Hanmi Pharmaceutical is gearing up to make waves in the obesity drug market with its innovative Efpeglenatide, a "Korean-customized" treatment currently in Phase 3 trials and expected to launch in 2027. This GLP-1 receptor agonist promises safe weight loss with minimal side effects, while Hanmi also explores two additional candidates, HM15275 and HM17321, to cater to various obesity challenges.